Medically-enhanced normality: An alternative perspective on the use of medicines for non-medical purposes

International Journal of Pharmacy Practice

Volumn 11, Issue 4, 2003, Pages 243-249

  Møldrup, Claus ^a   Traulsen, Janine Morgall ^a   Almarsdóttir, Anna Birna ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF ICELAND   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ERYTHROPOIETIN; FINASTERIDE; GROWTH HORMONE; INFLUENZA VACCINE; MINERAL; MINOXIDIL; ORAL CONTRACEPTIVE AGENT; PLANT MEDICINAL PRODUCT; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; VITAMIN;

ADOLESCENT; ADULT; AGED; CHILD; CONCEPT FORMATION; DENMARK; DOPING; DRUG USE; DRUG UTILIZATION; ECONOMIC ASPECT; FAMILY LIFE; FEMALE; HUMAN; INTERNET; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICALLY ENHANCED NORMALITY; PRIORITY JOURNAL; PUBLIC OPINION; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SAMPLING; TELEPHONE; UTILIZATION REVIEW; WORK;

EID: 0348011746     PISSN: 09617671     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357022683     Document Type: Review

References (60)

1. Nutton V. The rise of medicine. In: Porter R, editor. Medicine. Cambridge: Cambridge University Press; 1996. p52-82.
2. Gross P, Hitzler R, Horner A. Zwei Kulturen? Diagnostische und terapeutische Kompetenz im wandel. Österr Zeitschrift fur Sozologie (Sonderheft, Medizinsoziologie); 1985.
3. Brock D. The use of drugs for pleasure - some philosophical issues. In: Murray T, Gaylin W, Macklin R, editors. Feeling good and doing better: Ethics and nontherapeutic drug use. Clifton, New Jersey: Humana Press; 1984. p83-106.
4. Shapiro MH. The technology of perfection: performance enhancement and the control of attributes. Southern California Law Review 1991;65:11-113.
5. Audran M, Gareau S, Matecki F, Durand F, Chenard C, Sicart M, et al. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sport Exerc 1999;31:639-45.
6. Waddington I. Sport, health and drugs: a critical sociological perspective. London: E & FN Spon; 2000.
7. Donohoe T, Johnson N. Foul play. Drug abuse in sports. New York: Basil Blackwell Ltd; 1986.
8. Kuhn C, Scott S, Wilke W. The straight facts about the most used and abused drugs from alcohol to ecstasy. New York: Norton; 1998.
9. Sherlock K, Conner M. Patterns of ecstasy use amongst club-goers on the UK 'dance scene'. Int J Drug Pol 1999;10:17-29.
10. Møldrup C. Den medicinerede normalitet. Copenhagen: Gyldendal; 1999.
11. Møldrup C. Fremtidens medicinske optimerede krop. In: Balling G, editor. Copenhagen: Experimentariet og Det Etiske Råd; 2000.
12. Møldrup C, Morgall JM. Risk society - reconsidered in a drug context. Health, Risk Soc 2001;3:59-74.
13. Slomka J. Playing with propranolol. Hastings Center Report 1992;22:13-7.
14. Ward D, Morgenthaler J, Fowkes SW. Smart drugs II: The next generation. New drugs and nutrients to improve your memory and increase your intelligence. California: Smart Publications; 1993.
15. Ward D, Morgenthaler J, Fowkes SW. Smart drugs and nutrients: How to improve your memory and increase your intelligence using the latest discoveries in neuroscience. California: Smart Publications; 1991.
16. Gordon L. Woman's body, woman's right, Birth control in America. New York: Penguin Books; 1974.
17. Brown NM. The life of the pill. Research/Penn State 1995;16 (number 1).
18. Asbell B. The pill: A biography of the drug that changed the world. New York: Random House; 1995.
19. Lewis J. Feminism, the menopause and hormone replacement therapy. Feminist Rev 1993;43(spring):38-56.
20. Duckitt K. Feminine forever? Woman Med 1990; January:10-11.
21. Greer G. The change. London: Hamish Hamilton; 1991.
22. Petersson B. Reproduktionsteknologi - umodenhed og misundelse. In: Rodenbeck B, Schott RM, editors. Copenhagen: Museum Tusculanums forlag; 1995.
23. Brunett AL. Viagra and women. John Hopkins Health Insider; 1998.
24. Hyman DA. Aesthetics and ethics: the implications of cosmetic surgery. Persp Biol Med 1990;33:190-202.
25. Danish Medicines Agency. Register of Medicinal Product Statistics. http://www.laegemiddelstyrelsen.dk/en/statistics/ products/5-year.asp
26. Tyrer P. Current status of beta-blocking drugs in the treatment of anxiety disorders. Drugs 1988;36:773-83.
27. Lockwood AH. Medical problems of musicians. New Engl J Med 1989;320:221-7.
28. Brandfonbrener AG. Beta-blockers in the treatment of performance anxiety. Med Prob Perform Art 1990;5:23-6.
29. James I, Savage I. Beneficial effect of nadolol on anxiety induced disturbances of performance in musicians - a comparison with diazepam and placebo. Am Heart J 1984;108:1150-5.
30. Brantigan CO, Brantigan TA, Joseph N. Effect of beta blockade and beta stimulation on stage fright. Am J Med 1982;72:88-94.
31. Nubé J. Beta-blockers: effects on performing musicians. Med Prob Perform Art 1991;6:61-88.
32. Clark D. Performance related medical and psychological disorders in instrumental musicians. Ann Behav Med 1989;11:28-34.
33. Wright R. The coverage of happiness: when Prozac meets universal coverage. New Republic 1994;210:24-9.
34. Knutson B, Wolkowitz O, Cole S, Chan T, More E, Johnson R, et al. Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry 2001;155:373-9.
35. Ingvar M, Ambros-Ingerson J, Davis M, Granger R, Kessler M, Rogers G, et al. Enhancement by an ampakine of memory encoding in humans. Exp Neurol 1997;146:553-9.
36. Block W. Memory enhancement therapy. http://www.life-enhancement.com/article_template.asp?ID=517
37. Marciniak RA, Lombard DB, Johnson FB, Guarente L. Nucleolar localization of the Werner syndrome protein in human cells. Proc Natl Acad Sci 1998;95:6887-92.
38. Cohen P. Elixir of youth. New Scientist 1997; September 6:14.
39. Parens E. The goodness of fragility: on the prospect of genetic technologies aimed at the enhancement of human capacities. Kennedy Institute of Ethics Journal 1995;5:141-53.
40. Gardner W. Can human genetic enhancement be prohibited? J Med Philos 1995;20:65-84.
41. Anderson WF. Genetic engineering and our humanness. Hum Gene Ther 1994;5:755-9.
42. Military Health Services Systems. Focused study on biotechnology and nanotechnology 2020. Washington DC, Deputy Assistant Secretary of Defence (Health Affairs) Defence Pentagon; 1997.
43. Juengst ET. Can enhancement be distinguished from prevention in genetic medicine? J Med Philos 1997;22:127-42.
44. Woudenberg F. An evaluation of Delphi. Technolog Forecast Soc Change 1991;40:131-50.
45. Ziglio E. The Delphi method and its contribution to decision-making. In: Adler M, Ziglio E, editors. Gazing into the oracle - The Delphi method and its application to social policy and public health. London: Jessica Kingsley Publishers; 1996.
46. Turoff M, Hiltz SR. Computer-based Delphi processes. In: Alder M, Ziglio E, editors. Gazing into the oracle - The Delphi method and its application to social policy and public health. London: Jessica Kingsley Publishers; 1996.
47. Møldrup C. Risk of future drugs - expert and citizen perspectives. Copenhagen: The Royal Danish School of Pharmacy; 2000.
48. Møldrup C, Morgall JM. Risk of future drugs - A Delphi expert study. Technolog Forecast Soc Change 2001;67:273-89.
49. Befolkningen. Copenhagen: Danmarks Statistik; 1999.
50. Duch M, Windfelt N. Dansk Internetrapport. Aarhus: envision; 1999.
51. Lilja J. Theoretical social pharmacy - the drug sector from a social science perspective. Kuopio: University of Kuopio; 1988.
52. Hunt LM, Jordan B, Irwin S, Browner CH. Compliance and the patient's perspective: controlling symptoms in everyday life. Culture Med Psychiatry 1989;13:315-34.
53. Blaxter M, Britten N. Lay beliefs about drugs and medicines and the implications for community pharmacy. A review paper. Manchester: Pharmacy Practice Research Resource Centre; 1996.
54. Conrad P. The meaning of mediciations: another look at compliance. Soc Sci Med 1985;20:29-37.
55. Morgall JM, Almarsdóttir A. The new consumer - implications for pharmacy. Int J Pharm Pract 1999;7:198-201.
56. Møldrup C, Morgall JM, Almarsdóttir A. Perceived risk of future drugs - Danish citizens Delphi. Health Risk Soc 2002;4:5-17.
57. Møldrup C, Morgall JM, Almarsdóttir A. Citizens involvement in drug research and development - Danish citizens Delphi. Forsight 2000;5:452-62.
58. Foucault M. The birth of the clinic. London: Tavistock; 1973.
59. Foucault M. The history of sexuality. Harmodsworth: Penguin; 1979.
60. McCorquodale D. Orlan: This is my body ... this is my software. London: Black Dog; 1996.